Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ramana M. V. Reddy"'
Autor:
Stephen C. Cosenza, Amol Padgaonkar, Ramana M. V. Reddy, Hanna Y. Irie, E. Premkumar Reddy, Katsutoshi Sato, Stacey J. Baker
Publikováno v:
Cancer Research. 80:P5-05
Background/Rationale: Sensitivity to chemotherapy is a strong, consistent predictor of survival for patients diagnosed with triple negative breast cancer (TNBC) and chemotherapy resistance remains a critical problem for a subset of patients. Cancer c
Autor:
Premkumar E Reddy, Sachin Bansal, Duraiswamy A. Jeyaraj, Srinivas Maddi, Joshodeep Boruwa, Chandra Deb, Pratima Srivastava, Srinivas Lenkalapelly, Ramana M. V. Reddy, Ravi Akkireddy, Manoj Maniar, Arnab Roy Chowdhury, Jang B. Gupta
Publikováno v:
ADMET and DMPK
Volume 4
Issue 4
Volume 4
Issue 4
GBO-006 was shown to be a highly specific and selective PLK2 inhibitor that promoted mitotic arrest in various cancer cell lines, subsequently resulting in their apoptotic death. Intraperitoneal alternate day dosing of GBO-006 using 100 % DMSO as for
Publikováno v:
Blood. 85:2162-2170
Chronic myelogenous leukemia is characterized by the Philadelphia chromosome, which at the molecular level results from the fusion of the bcr gene on chromosome 22 and the abl gene on chromosome 9. The bcr-abl fusion gene encodes a novel tyrosine kin
Autor:
Chen Ren, Daniel Fox, Ramana M. V. Reddy, Muralidhar R. Mallireddigari, Benjamin S. Hoffman, Manoj Maniar
Publikováno v:
Molecular Cancer Therapeutics. 14:LB-A21
Introduction: Recent proof-of-concept for targeting cyclin dependent kinases 4 and 6 (CDK4/6) culminated in the approval for breast cancer of the first-in-class CDK4/6 inhibitor, palbociclib (Ibrance®). Palbociclib and other potent but narrowly targ
Autor:
Rodrigo Vasquez-Del Carpio, E. Premkumar Reddy, Kaushik Dutta, Aneel K. Aggarwal, Sai Krishna Athaluri Divakar, Ramana M. V. Reddy, Stacey J. Baker
Publikováno v:
Blood. 124:5616-5616
Oncogenic activation of RAS via point mutations occurs in more than 30% of all human cancers, including hematopoietic malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Investigations to understand the critical bioc
Autor:
Chandra Deb, Ramana M. V. Reddy, Shashidhar S. Jatiani, Stephen C. Cosenza, Arnab Roychowdhury, Amol Padgaonkar, Srinivasarao Maddi, Sayan Mitra, Premkumar E Reddy, Athisayamani Jeyaraj Duraiswamy, Manoj Maniar
Publikováno v:
Cancer Research. 74:4537-4537
Introduction: The goal of this study was to develop a targeted therapy for triple negative breast cancer (TNBC) since these tumors do not respond to hormonal-related therapies or medications that target HER2. TNBC is typically treated with a combinat
Publikováno v:
Cancer Research. 71:4524-4524
Oncology drug discovery is constantly evolving by integrating new basic findings with established developmental practice. Two drug discovery platforms currently exist. One is an extension of basic research, rational drug design. Its alternative, one
Autor:
Amanda M. Gillum, Jerome E. Groopman, E. Premkumar Reddy, Ramana M. V. Reddy, Anil Prasad, Ashutosh Shrivastava
Publikováno v:
Blood. 116:771-771
Abstract 771 Mantle cell lymphoma (MCL) is a well-defined subtype of B-cell non-Hodgkin's lymphoma characterized by a t(11;14)(q13;q32) chromosomal translocation, and associated with constitutive over-expression of cyclin D1. MCL generally has poor c
Autor:
Jerome S. Groopman, Premkumar E Reddy, Elaine M. Sloand, Ramana M. V. Reddy, Neal S. Young, Loretta Pfannes
Publikováno v:
Blood. 110:822-822
Trisomy 8 CD34 cells persist and even expand in patients with bone marrow failure despite a potent specific immune response against them(Sloand EM et al; Blood2005; 106(3):841). We previously demonstrated dramatic increases in c-myc, survivin, and CD